EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусскийTürkçeאנגלית 9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook ...
Medscape - Multiple indication dosing for Gleevec, Imkeldi (imatinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
The Novartis spokeswoman also referred to third-party articles, saying an enormous amount of resources was required to develop a successful drug such as Gleevec, without elaborating its total cost. However, despite the consensus that innovation and discoveries must be rewarded and pharmaceutical companie...
PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)Research paper, Faculty of Commerce and Administration (M.B.A.) -- Concordia University, 1992. Includes bibliographical references (leaves 56-67)....
PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)doi:10.1016/S1098-3015(10)65736-1K El Ouagari and W Talbot and JF BaladiValue in Health
PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)doi:10.1016/s1098-3015(10)65736-1K El OuagariW TalbotJF Baladi
The author discusses aspects of the case concerning the patent for the Gleevec anti-cancer drug from Novartis AG. He praises the judgment of the two judges on April 1, 2013. He states that the dismissal of the claims opens the door for generics manufacturing, which lower the cost of ...